Adhere+ Expands Remote Therapeutic Monitoring Capabilities with 10 New Protocols Tailored to Clinical Demand

Latest additions address chronic pain, geriatrics, rheumatology, and neuromodulation, supporting more personalized and proactive outpatient care

WASHINGTON, Sept. 2, 2025 /PRNewswire/ — Adhere+, a telehealth company focused on improving patient outcomes through a SaaS-based telehealth care plan adherence and medication compliance technology platform, today announced the launch of ten new and updated clinical protocols designed to enable providers to remotely manage a broader group of patients while providing continuous care across high-need chronic patient populations. Developed in collaboration with health system physician provider partners, these condition-specific protocols expand the company’s library of engagement tools to support proactive management of chronic pain, autoimmune disorders, and aging-related health issues.

The newly released protocols include clinical question protocols for geriatrics, fibromyalgia, rheumatoid arthritis, lupus, psoriatic arthritis, and a suite of tools supporting neuromodulation, opioid management, and ReActiv8 therapy for chronic low back pain. Each protocol is optimized for asynchronous interaction, allowing patients to report symptoms, function, and medication use on their own schedule, yielding real-time insights that support timely clinical intervention.

“We developed these protocols in direct response to provider demand,” said Jim Breidenstein, Chief Executive Officer of Adhere+. “The premise of our Platform is to titrate clinical question protocols to specific clinical use cases in flexible, scalable ways to stay connected to patients with complex conditions. These tools help them do exactly that by improving engagement, reducing risk, and supporting better outcomes in the outpatient setting.”

Since launching its Platform, Adhere+ has collected over 3 million electronic patient reported outcomes (ePros), and now is adding almost 250,000 ePros data points a month, demonstrating the power of asynchronous engagement to fill gaps left by episodic care. These additional and/or expanded protocols reinforce the Platform’s versatility, enabling remote telehealth monitoring across a broader array of specialties without burdening clinical staff or requiring new technical investment. All protocols are customizable to meet the needs of a broad array of clinician providers treating chronic patients. By offering targeted, condition-specific question libraries within a unified RTM infrastructure, Adhere+ continues to support a scalable, patient-centered approach to modern care delivery.

About Adhere+

Adhere+ is a medical treatment compliance platform, focused on creating a personalized pathway to support chronic care interventions for patients suffering from chronic care treatment conditions including pain, opioid/substance use disorders (SUD) and obesity.  The SaaS platform is technology based, clinically validated via ten (10) published and peer-reviewed clinical trials.  The Adhere+ approach is a user-friendly, digital platform to provide the physician with daily, evidence-based telehealth ePros interventions to improve patient compliance with treatment protocols, leading to better health outcomes, and a reduction in related healthcare costs.  The program aligns with several AMA CPT payment codes for a potential reimbursable benefit.

Contact

Investors:
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com  

Media:
Tiberend Strategic Advisors, Inc.
Eric Reiss
ereiss@tiberend.com 

Adhere+:
Dan Cohen, President and Co-Founder
202-329-1825
dlc@adhereplus.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/adhere-expands-remote-therapeutic-monitoring-capabilities-with-10-new-protocols-tailored-to-clinical-demand-302543079.html

SOURCE Adhere+

Staff

Recent Posts

Lightera Advances Fiber-integrated Temperature Feedback for Safer Laser-based Medical Procedures

SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ -- BiOS - Hall D Booth #8430, Photonics West Hall…

18 hours ago

DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx(TM) Red Eye

Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE:…

23 hours ago

NuGen Medical Devices Provides 2025 Year End Update on R&D and Strategic Progress

Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"…

24 hours ago

University of Phoenix and LinkedIn to host webinar on AI in nursing with skills and strategies for a new era of healthcare

January 22 virtual event "AI in Action: Skills and Strategies for a New Era of…

24 hours ago

Instinct Science Acquires ScribbleVet to Deliver the Next Generation of Intelligent-Native Veterinary Practice Management Software

The combination redefines PIMS by embedding AI, workflow, and clinical intelligence into a single system…

24 hours ago

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…

1 day ago